Screening and Patient Assessment

Teaches how to assess clinical suitability before psychedelic or ketamine treatment, including medical and psychiatric screening, readiness evaluation, contraindication review, inclusion/exclusion criteria, and ongoing eligibility re-checks before dosing.

8 care stages · 52 guidelines · 15 courses · 12 providers

Teaches structured assessment of suicidal ideation, intent, psychiatric deterioration, and related high-risk presentations. Learners are trained to use appropriate tools, safety planning, emergency contacts, clinician access, and escalation pathways when risk is identified.

7 care stages · 41 guidelines · 1 courses · 1 providers

Ability to perform or supervise detailed psychiatric evaluation for diagnosis, eligibility, and ongoing monitoring. The therapist/facilitator must understand symptom presentations relevant to MDD, AUD, suicidality, psychosis, and dissociation.

4 care stages · 9 guidelines · 0 courses · 0 providers

Therapists and study clinicians perform detailed biopsychosocial interviewing during preparation and screening. This supports treatment planning, risk assessment, and therapeutic understanding.

5 care stages · 7 guidelines · 0 courses · 0 providers

Teaches structured clinical interviewing and assessment administration for PTSD and related symptom domains, including symptom severity, functional impairment, risk factors, and appropriate use of standardized assessment tools.

7 care stages · 7 guidelines · 0 courses · 0 providers

Therapists/investigators must understand the medical suitability requirements for LSD-assisted psychotherapy and coordinate medication washout and concomitant medication review. This includes recognizing drug-drug interaction risks and contraindications.

3 care stages · 6 guidelines · 0 courses · 0 providers

Ability to administer and interpret structured interviews, clinician ratings, and self-report measures used in the study. Therapists contribute to eligibility, safety, and outcome assessment.

7 care stages · 5 guidelines · 0 courses · 0 providers

Therapists/facilitators need judgment about dosing and setting so experiences remain tolerable and therapeutically useful. The paper repeatedly notes that when dose and setting are appropriate, emerging material remains within the patient’s capacity to cope.

3 care stages · 5 guidelines · 0 courses · 0 providers

Know the medical and psychiatric exclusions that protect participants from foreseeable harm. Facilitators must recognize conditions that make MDMA-assisted psychotherapy unsafe or inappropriate.

4 care stages · 5 guidelines · 0 courses · 0 providers

Facilitator must understand opioid use disorder, medication-assisted treatment, and the clinical rationale for adjunctive psychotherapy. The protocol frames MORE+KAP as an investigational augmentation to buprenorphine treatment.

4 care stages · 4 guidelines · 0 courses · 0 providers

Therapists/facilitators must know the psychiatric and medical conditions that make KPT unsafe or inappropriate. Safe practice depends on excluding high-risk individuals.

3 care stages · 4 guidelines · 0 courses · 0 providers

Facilitators must competently administer and interpret clinician-rated ADHD and global severity measures. Accurate scoring is essential because these scales determine eligibility and outcomes.

4 care stages · 4 guidelines · 0 courses · 0 providers

Ability to evaluate alcohol and other substance use patterns using standardized tools and clinical interview. This is essential for eligibility, safety, and outcome monitoring.

4 care stages · 4 guidelines · 0 courses · 0 providers

Teaches screening for MRI contraindications and coordination of imaging clearance before scan procedures. The competency prevents exposure of ineligible participants to magnetic-resonance risks and supports safe imaging-session logistics.

3 care stages · 3 guidelines · 0 courses · 0 providers

Evaluates opioid withdrawal symptoms and tracks changes over time in participants discontinuing methadone OST. Uses standardized withdrawal ratings to assess potential treatment effects and safety.

4 care stages · 3 guidelines · 0 courses · 0 providers

Understand the major medical risks associated with ibogaine administration, especially cardiac and neurologic toxicity, before proceeding with treatment. This includes recognizing that ibogaine has been linked to torsades de pointes, QTc prolongation, bradycardia, and ataxia.

4 care stages · 3 guidelines · 0 courses · 0 providers

Administer and interpret psychological and psychometric measures relevant to mood, cravings, expectations, mystical experience, ego dissolution, and functioning. Facilitators must accurately support questionnaire-based assessment across time points.

5 care stages · 3 guidelines · 0 courses · 0 providers

Ability to monitor for opioid use recurrence, other substance use, and ketamine misuse during the trial. The clinician must recognize relapse risk and take action when substance use worsens.

3 care stages · 3 guidelines · 0 courses · 0 providers

Therapists need a solid professional background in psychotherapy, especially PTSD treatment. Prior experience with established trauma therapies and related approaches is considered important preparation for this work.

4 care stages · 3 guidelines · 0 courses · 0 providers

Understands and applies the protocol-defined criteria for treatment-resistant major depressive disorder, including diagnostic confirmation, episode severity, and prior treatment failure requirements. Must verify both current and historical antidepressant nonresponse and ensure the participant remains eligible at baseline.

3 care stages · 3 guidelines · 0 courses · 0 providers

The therapist must exercise clinical judgment about who may benefit, who may have difficulty surrendering defenses, and where evidence is limited. The handbook emphasizes uncertainty, need for research, and cautious selection based on insecurity, rigidity, suspicion, diagnosis, and treatment goals.

3 care stages · 2 guidelines · 0 courses · 0 providers

Uses assessment findings to individualize therapy and medication-session preparation. Adapts the approach based on participant response, goals, and clinical presentation.

4 care stages · 2 guidelines · 0 courses · 0 providers

Collect and interpret baseline behavioral, psychiatric, and medical history relevant to psilocybin research. This information is used to determine eligibility and contextualize outcomes.

4 care stages · 2 guidelines · 0 courses · 0 providers

Understands the clinical and occupational context of the treated population. Facilitators should be aware that the target group consisted of frontline physicians and nurses with depression and burnout related to the COVID-19 pandemic.

1 care stage · 2 guidelines · 0 courses · 0 providers

Because interviews and questionnaires may provoke emotional reactions or fatigue, facilitators must respond supportively and mitigate burden. This includes addressing distress during assessments and offering breaks.

4 care stages · 2 guidelines · 0 courses · 0 providers

Balances potential symptom relief against known and emerging safety risks in participants with opioid dependence. Makes conservative decisions when cardiac or adverse-effect concerns outweigh anticipated benefit.

2 care stages · 2 guidelines · 0 courses · 0 providers

Therapists/facilitators require knowledge of treating patients with moderate-to-severe major depressive disorder in the context of psychedelic-assisted therapy. The target population in the trial establishes disorder-specific clinical knowledge needs.

1 care stage · 2 guidelines · 0 courses · 0 providers

Therapists/facilitators should know the main assessment domains used in KPT research and clinical monitoring, including craving, depression, anxiety, anhedonia, addiction severity, and purpose in life. This knowledge supports case formulation and tracking change.

2 care stages · 2 guidelines · 0 courses · 0 providers

Ability to apply KAP flexibly across multiple diagnostic presentations. The article describes benefit in patients with a wide variety of diagnoses.

1 care stage · 1 guidelines · 0 courses · 0 providers

Ensure required abstinence conditions are met before dosing and make clinical judgments about rescheduling or exclusion when they are not. This protects safety and protocol integrity.

4 care stages · 1 guidelines · 0 courses · 0 providers

Understands diagnostic and clinical features of alcohol dependence and related severity measures used in the protocol. Uses this knowledge to inform eligibility, treatment focus, and outcome interpretation.

1 care stage · 1 guidelines · 0 courses · 0 providers

Clinicians must recognize the life-threatening nature of alcohol withdrawal and ensure adequate detoxification before treatment. Postponement and medical supervision are required when withdrawal risk is present.

3 care stages · 1 guidelines · 0 courses · 0 providers

The intervention targets anxiety associated with life-threatening diseases, so therapists need knowledge of the psychological burden of severe medical illness and the clinical presentation of anxiety in this population. They must be able to formulate treatment needs in medically ill patients.

1 care stage · 1 guidelines · 0 courses · 0 providers

Administer and interpret the study's psychosocial measures relevant to existential distress, depression, spiritual well-being, and death-related distress. These assessments are used for screening and outcome monitoring.

2 care stages · 1 guidelines · 0 courses · 0 providers

Before administration, facilitators should assess readiness and factors that could increase the chance of a difficult session. The source highlights that preoccupation, rigidity, low trust, and poor support can worsen experiences.

4 care stages · 1 guidelines · 0 courses · 0 providers

Evaluate whether a person is an appropriate candidate for ibogaine treatment by balancing potential benefit against medical risk. This includes identifying treatment-refractory opioid use disorder and weighing cardiotoxicity and other safety concerns against the harms of untreated substance use disorder.

2 care stages · 1 guidelines · 0 courses · 0 providers

Screen for cardiovascular risk before treatment because ibogaine may prolong the QT interval and has been linked to arrhythmias and deaths. Exclude or carefully manage patients with cardiac disease and other risk factors.

2 care stages · 1 guidelines · 0 courses · 0 providers

The conclusion emphasizes that findings apply to a selected group of patients, implying the importance of appropriate patient selection and caution in generalization when facilitating treatment.

1 care stage · 1 guidelines · 0 courses · 0 providers

Exclude or defer patients whose medical risk is too high, especially those with cardiovascular disease or other major contraindications. This is central to safer administration according to the source.

3 care stages · 1 guidelines · 0 courses · 0 providers

Knows the conditions that may disqualify a person from ketamine treatment and can apply that knowledge during screening. Recognizes medical, psychiatric, pregnancy-related, and substance-related contraindications.

1 care stage · 1 guidelines · 0 courses · 0 providers

Knowledge of anorexia nervosa symptomatology, risk, and clinical instability relevant to screening and treatment monitoring. The study requires awareness of eating-disorder-specific risks and outcomes.

2 care stages · 1 guidelines · 0 courses · 0 providers

Assess for physiologic factors that may increase ibogaine-related harm, especially electrolyte abnormalities. The source identifies electrolyte screening as part of safer administration.

4 care stages · 1 guidelines · 0 courses · 0 providers

After each MDMA session, therapists must assess whether continuing treatment is safe and clinically appropriate. The participant’s choice is respected unless safety concerns warrant exclusion.

2 care stages · 1 guidelines · 0 courses · 0 providers

Understands ibogaine as an intervention used for opioid dependence and withdrawal management. Can align treatment planning with addiction severity and withdrawal status.

1 care stage · 1 guidelines · 0 courses · 0 providers

Can evaluate whether ibogaine is being considered in the context of a highly selected clinical case, based on the source’s description of a severe, treatment-refractory patient. This includes understanding the limited evidence base and the need for careful patient selection.

1 care stage · 1 guidelines · 0 courses · 0 providers

Exercises heightened ethical responsibility when working with people with opioid dependence undergoing medication changes. Ensures participation remains voluntary, monitored, and clinically appropriate.

2 care stages · 1 guidelines · 0 courses · 0 providers

Determine whether a patient is intoxicated enough to impair participation in preparation sessions. This requires clinical judgment focused on comprehension and therapeutic alliance.

2 care stages · 1 guidelines · 0 courses · 0 providers

Therapists must know what constitutes adequate prior treatment exposure before considering study enrollment. This requires familiarity with accepted PTSD treatments and minimum duration/intensity standards.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators need competence in working with PTSD when comorbid conditions are present. The source explicitly notes dissociation, depression, alcohol/substance use disorders, and childhood trauma.

1 care stage · 1 guidelines · 0 courses · 0 providers

Ask about symptoms and adverse effects in a neutral, non-suggestive manner. This reduces bias and improves safety detection in a vulnerable oncology population.

2 care stages · 1 guidelines · 0 courses · 0 providers

Facilitators should conduct individual interviews to understand the person, their motivations, and current condition. The interview also helps identify changes since any prior session.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understands the clinical profile of opioid use disorder and identifies individuals with opioid dependence who may be considered for ibogaine-based detoxification in observational or treatment settings.

1 care stage · 1 guidelines · 0 courses · 0 providers

Clinicians must identify appropriate participants and recognize that the study enrolled psychiatrically healthy nicotine-dependent smokers. Competence includes screening for psychiatric suitability and tobacco dependence characteristics relevant to treatment eligibility.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understands the clinical context of switching participants from methadone to morphine before study participation. Appreciates how opioid substitution transitions can affect symptom interpretation and safety monitoring.

1 care stage · 1 guidelines · 0 courses · 0 providers

Knowledge of the patient populations and symptom profiles for which KAP may be considered, particularly depression, anxiety, PTSD, and treatment-resistant presentations. The article highlights benefit across a wide variety of diagnoses, with notable improvement in depression and anxiety.

1 care stage · 1 guidelines · 0 courses · 0 providers

Applies cautious patient selection when considering ibogaine for opioid detoxification, particularly for individuals with refractory opioid use disorder.

1 care stage · 1 guidelines · 0 courses · 0 providers

The therapist/facilitator must ensure medical suitability before ayahuasca administration by checking for conditions that increase risk. Screening should include physical exam, laboratory testing, and pregnancy assessment when indicated.

3 care stages · 1 guidelines · 0 courses · 0 providers

Conduct or support psychiatric screening using clinical interviews and structured diagnostic tools. The goal is to establish baseline mental health status and detect exclusionary disorders or instability.

2 care stages · 1 guidelines · 0 courses · 0 providers

Conducts a retrospective psychiatric interview to judge minimal clinical improvement on the current antidepressant regimen. Uses multiple information sources and clinical observation to determine whether the participant meets screening requirements.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists must monitor a clinically vulnerable population experiencing recent loss and possible PGD risk. The protocol requires special attention to psychological destabilization, distress, and functional impairment.

2 care stages · 1 guidelines · 0 courses · 0 providers

Therapists must assess the participant’s social support network and help plan appropriate use of supportive relationships during treatment. They should guide participants about the potential benefits and risks of sharing their experiences with others.

4 care stages · 1 guidelines · 0 courses · 0 providers

Understands the screening instruments and the respective roles of site staff and independent raters. The facilitator must collaborate with rater findings while maintaining appropriate boundaries and blinding.

1 care stage · 1 guidelines · 0 courses · 0 providers

Organizers must decide whether to accept or refuse participants based on screening and interview data. When in doubt, the guidance favors non-acceptance.

1 care stage · 1 guidelines · 0 courses · 0 providers

Ability to conduct initial phone-based screening to determine whether a potential participant appears eligible for the protocol. This requires efficient, accurate triage before in-person assessment.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists should meet formal licensure requirements and have specific prior training and experience in ketamine-assisted psychotherapy. Competence is not generic psychotherapy alone but includes psychedelic/ketamine-specific preparation and familiarity with the study population.

1 care stage · 1 guidelines · 0 courses · 0 providers

Conducts evaluations and psychotherapy with sensitivity to distress, moral injury, grief, and burnout. The therapist must avoid unnecessary burden while still collecting required data.

1 care stage · 1 guidelines · 0 courses · 0 providers

Understand PTSD, complex trauma, avoidance, dissociation, attachment disruption, and moral injury in order to interpret clinical material accurately and flexibly. Diagnosis-specific knowledge informs judgment without making the treatment protocol rigid.

1 care stage · 1 guidelines · 0 courses · 0 providers

Use a caring, natural, and non-threatening interview style to assess psychiatric and psychological domains. The protocol emphasizes normalization, reduction of guilt, symptom exaggeration techniques, and a logical flow that facilitates rapport.

2 care stages · 1 guidelines · 0 courses · 0 providers

The facilitator must understand why bipolar II participants require enhanced monitoring and conservative dosing. The protocol is built around the risk of mood destabilization in this population.

4 care stages · 1 guidelines · 0 courses · 0 providers

Understand the domains assessed in the Storyline psychiatric and neurological interviews and use this knowledge to support accurate administration and interpretation of study tasks. Domains include cognition, mood, homeostasis, social support, and psychosis/suicidality screening.

4 care stages · 1 guidelines · 0 courses · 0 providers

The study relied on self-reported symptomatology, so clinicians should understand how to gather and interpret patient-reported outcomes relevant to psychiatric and existential distress. This includes using subjective reports as meaningful indicators while recognizing their limits.

2 care stages · 1 guidelines · 0 courses · 0 providers

The curriculum includes practical assessment work and use of intake templates and assessment forms. Students learn to evaluate client fit and tailor support based on client goals and needs.

3 care stages · 0 guidelines · 1 courses · 1 providers

Teaches recognition and documentation of dissociation, psychosis-like symptoms, mania, and other acute neuropsychiatric effects that can occur after ketamine, psychedelic dosing, or related interventions. The focus is monitoring, reporting, and escalation when symptoms become clinically significant.

7 care stages · 12 guidelines · 0 courses · 0 providers

Teaches structured monitoring of depressive symptoms, response, and remission across treatment and follow-up. Learners use standardized scales and clinical review to track change and identify deterioration or non-response.

6 care stages · 10 guidelines · 0 courses · 0 providers

Teaches clinicians and research staff to understand the purpose, limits, scoring, interpretation, and clinical meaning of psychological measures and study instruments used to evaluate symptoms, functioning, safety, and treatment outcomes.

7 care stages · 9 guidelines · 0 courses · 0 providers

Cluster covering 2 related competencies including: Preparation of set and setting, Client preparation and therapeutic set/setting.

6 care stages · 8 guidelines · 2 courses · 2 providers

Teaches how clinicians determine whether a participant should proceed, pause, discontinue dosing, or terminate study participation. The competency centers on safety-driven clinical judgment, risk-benefit assessment, and early termination when continuation is no longer appropriate.

6 care stages · 8 guidelines · 0 courses · 0 providers

The study used standardized anxiety measures and followed patients for 2 months and 12 months, implying competence in tracking outcomes over time. Therapists should be able to assess symptom change and sustained benefit using structured follow-up.

5 care stages · 8 guidelines · 0 courses · 0 providers

The therapist/facilitator must support structured dose escalation decisions within the individualized dosing regimen. Decisions depend on both patient-reported peak experience and clinical tolerability/safety judgments.

2 care stages · 7 guidelines · 0 courses · 0 providers

Teaches counseling and monitoring around contraception, reproductive restrictions, pregnancy risk, and pregnancy-related discontinuation rules. Learners are trained to explain requirements clearly and respond promptly when pregnancy or reproductive-safety concerns arise.

5 care stages · 6 guidelines · 0 courses · 0 providers

Cluster covering 5 related competencies including: Concomitant medication review, Contraindication and interaction awareness, Contraindications, drug effects, and interactions.

5 care stages · 5 guidelines · 1 courses · 1 providers

Therapists/facilitators should be able to judge whether therapeutic change reaches clinically meaningful thresholds, not just whether symptoms improve numerically. This supports informed ongoing care and communication about benefits and limitations.

6 care stages · 5 guidelines · 0 courses · 0 providers

Administer study measures and structured assessments on schedule, including psychological, spiritual, and neurobehavioral instruments. This includes both paper-based and Storyline-based assessments.

5 care stages · 5 guidelines · 0 courses · 0 providers

The framework implies competence in evaluating both symptom change and subjective outcomes over time. The study used standardized anxiety measures and qualitative interviews to assess sustained effects and patient-reported change.

4 care stages · 3 guidelines · 0 courses · 0 providers

Monitor for ibogaine-associated cardiac toxicity, especially QTc prolongation and risk of torsades de pointes. This includes baseline exclusion screening, frequent ECG surveillance, and escalation when QTc becomes markedly prolonged.

3 care stages · 3 guidelines · 0 courses · 0 providers

Reviews laboratory and ECG data for clinically relevant abnormalities and determines whether continued participation is appropriate. Escalates abnormalities requiring repeat testing or specialist input.

2 care stages · 3 guidelines · 0 courses · 0 providers

The manual specifies baseline professional requirements for study therapists. These include licensure and substantial clinical experience with psychiatric populations.

3 care stages · 3 guidelines · 0 courses · 0 providers

Ability to administer standardized clinical ratings consistently and under supervision. Reliable measurement is essential for efficacy and safety endpoints.

4 care stages · 3 guidelines · 0 courses · 0 providers

Tailor therapeutic engagement to patients with advanced non-operable GI cancers facing existential distress, grief, and limited life expectancy. The therapist/facilitator must recognize the emotional and medical context of end-of-life suffering.

2 care stages · 3 guidelines · 0 courses · 0 providers

Although formal measurements may be conducted by another researcher, therapists/facilitators must work within a protocol that includes repeated anxiety assessments and daily diaries of anxiety, pain, and medication use. This implies competence in reinforcing adherence to monitoring procedures and integrating findings into care awareness.

3 care stages · 3 guidelines · 0 courses · 0 providers

Help patients engage in emotionally intense trauma-focused treatment and reduce dropout risk. The therapist should recognize comorbid depression or anxiety that may interfere with adherence and response.

5 care stages · 3 guidelines · 0 courses · 0 providers

Teaches the requirement for site personnel to be trained and certified on protocol-specific assessments, psychiatric instruments, rating scales, and study procedures before performing them in the trial.

4 care stages · 3 guidelines · 0 courses · 0 providers

Therapists must practice within the population and setting defined by the manual, limiting use to approved clinical trial subjects with PTSD. This boundary helps protect participants and preserves research integrity.

2 care stages · 2 guidelines · 0 courses · 0 providers

Review laboratory and biomarker data for clinically significant abnormalities, including chemistry, hematology, coagulation, and alcohol biomarkers. This supports medical safety surveillance during follow-up.

3 care stages · 2 guidelines · 0 courses · 0 providers

Performs targeted nasal examinations and assesses local tolerability of esketamine nasal spray. Identifies findings that could affect drug delivery, safety, or continuation.

3 care stages · 2 guidelines · 0 courses · 0 providers

Knowledge of the trial’s primary, secondary, and exploratory endpoints and the instruments used to assess them. This enables accurate administration and interpretation of study procedures.

4 care stages · 2 guidelines · 0 courses · 0 providers

Because cognitive performance during treatment is a named secondary outcome, clinicians involved in care should be able to monitor and document cognitive functioning relevant to treatment participation. This supports safety oversight and interpretation of treatment effects.

3 care stages · 2 guidelines · 0 courses · 0 providers

The therapist/facilitator or designated rater must administer and interpret multiple structured clinical scales reliably. Training and separation of roles are required to preserve rating quality and blinding.

3 care stages · 2 guidelines · 0 courses · 0 providers

Measure opioid withdrawal severity using standardized instruments and interpret symptom severity over time. Facilitators must be able to collect both objective observation and patient-reported data.

4 care stages · 2 guidelines · 0 courses · 0 providers

Teaches psychoactive substance pharmacology, expected drug effects, contraindications, and relevant drug-interaction risks. The competency supports safer screening, medication review, participant education, and clinical decision-making.

4 care stages · 1 guidelines · 2 courses · 2 providers

Competent delivery includes monitoring psychosocial functioning in addition to depressive symptoms. The source reports psychosocial functioning as a treatment outcome sustained through follow-up.

3 care stages · 1 guidelines · 0 courses · 0 providers

Trained staff must administer and/or supervise a battery of behavioral tasks and self-report instruments consistently across baseline and drug sessions. Some measures are verbally administered by clinicians or coordinators and require standardized delivery.

3 care stages · 1 guidelines · 0 courses · 0 providers

Clinicians must have working expertise in evidence-based CBT for depression and related mood conditions, including the ability to deliver core CBT components across preparation, post-session integration, and relapse prevention phases. The protocol assumes competence in standard CBT delivery as the psychosocial backbone of treatment.

4 care stages · 1 guidelines · 0 courses · 0 providers

Use pharmacogenetic information to anticipate altered ibogaine metabolism and exposure. The study identifies CYP2D6 activity as a major determinant of ibogaine clearance.

1 care stage · 1 guidelines · 0 courses · 0 providers

Ability to judge clinical worsening over time and determine whether a participant can remain in the study or requires higher-level care. This is a continuing monitoring responsibility throughout the trial.

1 care stage · 1 guidelines · 0 courses · 0 providers

Tracks dose-dependent changes without assuming full psychedelic effects. This includes recognizing that low-dose exposure may modulate brain activity while remaining sub-psychedelic.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists should proactively explore participants’ hopes, fears, concerns, and expectations about treatment and address them responsively.

1 care stage · 1 guidelines · 0 courses · 0 providers

Works with the combined clinical picture of chronic pain, depression, anxiety, and PTSD symptoms. Provides psychotherapy that is responsive to both somatic and psychiatric suffering.

2 care stages · 1 guidelines · 0 courses · 0 providers

Facilitators should understand the therapeutic and adverse-effect context of psilocybin and comparator antidepressant treatment, since the trial directly compared psilocybin with escitalopram.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists need specific knowledge of methamphetamine use disorder, HIV risk behaviors, and the social context of affected populations to deliver relevant and responsive care. This includes understanding how methamphetamine use intersects with trauma, sexual risk, and HIV prevention or treatment adherence.

1 care stage · 1 guidelines · 0 courses · 0 providers

Therapists in this setting must recognize abnormal cardiovascular responses and follow protocolized responses for hypertensive crisis, angina, myocardial infarction, or stroke.

2 care stages · 1 guidelines · 0 courses · 0 providers

Therapists/facilitators must monitor for adverse medical signs during sessions and obtain targeted testing when clinically indicated. Safety practice should balance participant comfort with symptom-triggered medical evaluation.

2 care stages · 1 guidelines · 0 courses · 0 providers

Screen for co-medications that may prolong QTc or affect CYP2D6 metabolism. This is critical to reduce confounding and prevent additive toxicity.

2 care stages · 1 guidelines · 0 courses · 0 providers

The protocol includes secondary outcomes for depression and anxiety severity, so clinicians should be able to assess and track these domains alongside PTSD symptoms. This broadens case monitoring and supports comprehensive clinical oversight.

2 care stages · 1 guidelines · 0 courses · 0 providers

Knowledge of placebo-controlled treatment design and the interpretive issues it raises in psychotherapy research. This supports appropriate understanding of efficacy findings.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators should understand that treatment aims include symptom reduction and improved functioning. Support work should attend to both emotional processing and real-world disability.

2 care stages · 1 guidelines · 0 courses · 0 providers

Knowledge of clinical trial methods and evaluation approaches relevant to psychotherapy research. The source indicates controlled clinical trial and analysis of variance contexts.

1 care stage · 1 guidelines · 0 courses · 0 providers

Clinicians must ensure participants meet day-of-session safety requirements before psilocybin is administered. This includes verifying toxicology, pregnancy, alcohol abstinence, and adherence to protocol restrictions.

3 care stages · 1 guidelines · 0 courses · 0 providers

Use Subjective Units of Distress Scale ratings to track fear activation and extinction during PE sessions. This requires eliciting reliable distress ratings and using them to guide exposure processing.

2 care stages · 1 guidelines · 0 courses · 0 providers

Therapists must understand that parts, selves, subpersonalities, or dissociative-like multiplicity can emerge normally, especially in trauma. They should not pathologize these experiences and should help use them therapeutically.

1 care stage · 1 guidelines · 0 courses · 0 providers

Facilitators require knowledge of the therapeutic context, including that psilocybin is being investigated as a rapid-acting treatment for major depressive disorder. This includes understanding the expected timeframe of symptom assessment and response.

2 care stages · 1 guidelines · 0 courses · 0 providers

Facilitators need conceptual knowledge of normal grief, prolonged grief disorder, and the rationale for preventive and therapeutic grief care. This informs formulation, pacing, and risk awareness in the protocol.

2 care stages · 1 guidelines · 0 courses · 0 providers

The therapist should assess both the immediate experience and longer-term change, using structured observation, self-report, and reports from others where possible. The handbook treats evaluation as difficult but necessary for understanding therapeutic effects.

3 care stages · 1 guidelines · 0 courses · 0 providers

Therapists should understand and address cognitive-affective mechanisms linked to improvement, particularly emotion regulation and positive and negative cognitive schemas. The study associated symptom improvement with changes in these domains.

1 care stage · 1 guidelines · 0 courses · 0 providers

Teaches work with clinically complex contexts such as trauma, palliative care, and other nuanced presentations where ethical judgment, scope discipline, careful assessment, and individualized support are required.

3 care stages · 0 guidelines · 2 courses · 1 providers

The page explicitly notes medication interactions, contraindications, and risk management for prescribers. This indicates training in identifying unsafe combinations and excluding or delaying treatment when needed.

3 care stages · 0 guidelines · 1 courses · 1 providers

Learners are taught to design custom protocols for both microdosing and macrodosing based on client goals. The page also references microdosing formulas and practical application of timing and dosage nuances.

4 care stages · 0 guidelines · 1 courses · 1 providers

The course teaches the overall PAP workflow from screening through follow-up. Learners are expected to understand and explain each phase of treatment in a structured way.

7 care stages · 0 guidelines · 1 courses · 1 providers